{"id":"https://openalex.org/W2802853266","doi":"https://doi.org/10.3233/jad-179934","title":"The Conundrum of GSK3 Inhibitors: Is it the Dawn of a New Beginning?","display_name":"The Conundrum of GSK3 Inhibitors: Is it the Dawn of a New Beginning?","alternate_titles":[],"publication_year":2018,"publication_date":"2018-05-11","ids":{"openalex":"https://openalex.org/W2802853266","doi":"https://doi.org/10.3233/jad-179934","mag":"2802853266","pmid":"https://pubmed.ncbi.nlm.nih.gov/29758944"},"language":"en","primary_location":{"id":"doi:10.3233/jad-179934","doi":"https://doi.org/10.3233/jad-179934","is_oa":false,"landing_page_url":"https://doi.org/10.3233/jad-179934","pdf_url":null,"source":{"id":"https://openalex.org/S25155249","display_name":"Journal of Alzheimer s Disease","issn_l":"1387-2877","issn":["1387-2877","1875-8908"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310318577","host_organization_name":"IOS Press","host_organization_lineage":["https://openalex.org/P4310318577"],"host_organization_lineage_names":["IOS Press"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Alzheimer's Disease","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2802853266"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5081853343","display_name":"Ratan V. Bhat","orcid":"https://orcid.org/0000-0002-7374-7039","observed_orcids":["https://orcid.org/0000-0002-7374-7039"]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ratan V. Bhat","raw_affiliation_strings":["Strategy and External Innovation, Cardiovascular, Renal and Metabolism Innovative Medicines and Early Development Biotech Unit, AstraZeneca R&D, Gothenburg, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Strategy and External Innovation, Cardiovascular, Renal and Metabolism Innovative Medicines and Early Development Biotech Unit, AstraZeneca R&D, Gothenburg, Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Ulf Andersson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ulf Andersson","raw_affiliation_strings":["Drug Safety and Metabolism, Innovative Medicines and Early Development Biotech Unit, AstraZeneca R&D, Gothenburg, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Safety and Metabolism, Innovative Medicines and Early Development Biotech Unit, AstraZeneca R&D, Gothenburg, Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049706887","display_name":"Shalini Andersson","orcid":"https://orcid.org/0000-0002-7051-2189","observed_orcids":["https://orcid.org/0000-0002-7051-2189"]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Shalini Andersson","raw_affiliation_strings":["Drug Metabolism and Pharmacokinetics, Innovative Medicines and Early Development Biotech Unit, AstraZeneca R&D, Gothenburg, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Metabolism and Pharmacokinetics, Innovative Medicines and Early Development Biotech Unit, AstraZeneca R&D, Gothenburg, Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075866797","display_name":"Laurent Knerr","orcid":"https://orcid.org/0000-0002-4810-8526","observed_orcids":["https://orcid.org/0000-0002-4810-8526"]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Laurent Knerr","raw_affiliation_strings":["Medicinal Chemistry Cardiovascular and Metabolic Disease, Innovative Medicines and Early Development Biotech Unit, AstraZeneca R&D, Gothenburg, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicinal Chemistry Cardiovascular and Metabolic Disease, Innovative Medicines and Early Development Biotech Unit, AstraZeneca R&D, Gothenburg, Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Udo Bauer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Udo Bauer","raw_affiliation_strings":["Strategy and External Innovation, Cardiovascular, Renal and Metabolism Innovative Medicines and Early Development Biotech Unit, AstraZeneca R&D, Gothenburg, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Strategy and External Innovation, Cardiovascular, Renal and Metabolism Innovative Medicines and Early Development Biotech Unit, AstraZeneca R&D, Gothenburg, Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5036885781","display_name":"Anna K. Sundgren\u2010Andersson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Anna K. Sundgren-Andersson","raw_affiliation_strings":["Cardiovascular, Renal and Metabolic disease, Global Medicines Development, AstraZeneca Gaithersburg, MD, USA","E-mail:"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cardiovascular, Renal and Metabolic disease, Global Medicines Development, AstraZeneca Gaithersburg, MD, USA","institution_ids":["https://openalex.org/I4210150756"]},{"raw_affiliation_string":"E-mail:","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.0114,"has_fulltext":false,"cited_by_count":103,"citation_normalized_percentile":{"value":0.71224887,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":97,"max":100},"biblio":{"volume":"64","issue":"s1","first_page":"S547","last_page":"S554"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.9541000127792358,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.9541000127792358,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10929","display_name":"Wnt/\u03b2-catenin signaling in development and cancer","score":0.019899999722838402,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10169","display_name":"Protein Kinase Regulation and GTPase Signaling","score":0.008700000122189522,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gsk-3-inhibitors","display_name":"GSK-3 inhibitors","score":0.9750000238418579}],"concepts":[{"id":"https://openalex.org/C70721500","wikidata":"https://www.wikidata.org/wiki/Q177005","display_name":"Computational biology","level":1,"score":0.3407383859157562},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3264073133468628},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2769165635108948}],"mesh":[{"descriptor_ui":"D000544","descriptor_name":"Alzheimer Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D000544","descriptor_name":"Alzheimer Disease","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D038362","descriptor_name":"Glycogen Synthase Kinase 3","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D038362","descriptor_name":"Glycogen Synthase Kinase 3","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.3233/jad-179934","doi":"https://doi.org/10.3233/jad-179934","is_oa":false,"landing_page_url":"https://doi.org/10.3233/jad-179934","pdf_url":null,"source":{"id":"https://openalex.org/S25155249","display_name":"Journal of Alzheimer s Disease","issn_l":"1387-2877","issn":["1387-2877","1875-8908"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310318577","host_organization_name":"IOS Press","host_organization_lineage":["https://openalex.org/P4310318577"],"host_organization_lineage_names":["IOS Press"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Alzheimer's Disease","raw_type":"journal-article"},{"id":"pmid:29758944","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29758944","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Alzheimer's disease : JAD","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.979200005531311,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":47,"referenced_works":["https://openalex.org/W299856585","https://openalex.org/W1483825698","https://openalex.org/W1496294957","https://openalex.org/W1513401887","https://openalex.org/W1528219518","https://openalex.org/W1567624342","https://openalex.org/W1577837690","https://openalex.org/W1960647274","https://openalex.org/W1973774127","https://openalex.org/W1979694143","https://openalex.org/W1980768099","https://openalex.org/W2001503094","https://openalex.org/W2006090252","https://openalex.org/W2014898742","https://openalex.org/W2018607550","https://openalex.org/W2021370614","https://openalex.org/W2024119654","https://openalex.org/W2031864556","https://openalex.org/W2035470211","https://openalex.org/W2046148144","https://openalex.org/W2051547572","https://openalex.org/W2055453151","https://openalex.org/W2058085247","https://openalex.org/W2058138221","https://openalex.org/W2063620211","https://openalex.org/W2064958479","https://openalex.org/W2073012903","https://openalex.org/W2075778898","https://openalex.org/W2082387343","https://openalex.org/W2093426751","https://openalex.org/W2099143291","https://openalex.org/W2101026479","https://openalex.org/W2112475172","https://openalex.org/W2119962765","https://openalex.org/W2127004861","https://openalex.org/W2144091853","https://openalex.org/W2152298579","https://openalex.org/W2156676059","https://openalex.org/W2161182074","https://openalex.org/W2161977058","https://openalex.org/W2168597028","https://openalex.org/W2258420810","https://openalex.org/W2339355315","https://openalex.org/W2751383955","https://openalex.org/W2969438869","https://openalex.org/W4211156109","https://openalex.org/W4293242696"],"related_works":["https://openalex.org/W7131286796","https://openalex.org/W3125256209","https://openalex.org/W2063620211","https://openalex.org/W2132570158","https://openalex.org/W1983435458","https://openalex.org/W2092506694","https://openalex.org/W3024435024","https://openalex.org/W2024496075","https://openalex.org/W2061072280","https://openalex.org/W2035167862"],"abstract_inverted_index":{"Spanning":[0],"over":[1],"three":[2],"decades":[3,47,219],"of":[4,25,48,55,61,91,100,106,143,154,174,194,206,217,220,231,253,261],"extensive":[5],"drug":[6,145,151,225,283],"discovery":[7,42,146,226,260],"research,":[8,49],"the":[9,23,53,56,59,81,98,104,107,112,128,141,164,168,192,212,229,258],"efforts":[10],"to":[11,79,103,114,158,166,187,235],"develop":[12],"a":[13,20,62,77,116,199,272,278],"potent":[14,85],"and":[15,34,45,58,72,83,86,111,123,130,180,182,222,277],"selective":[16,87],"GSK3":[17,88,109,144,150,224,237,282],"inhibitor":[18],"as":[19,198,255,257],"therapeutic":[21,117],"for":[22,171,239,274,281],"treatment":[24],"type":[26],"2":[27],"diabetes,":[28],"Alzheimer's":[29],"disease":[30,65],"(AD),":[31],"bipolar":[32],"disorders":[33],"cancer":[35],"have":[36,190,269],"been":[37,136],"futile.":[38],"Since":[39],"its":[40],"initial":[41],"in":[43,76,127,140,163,185,243,247],"1980":[44],"subsequent":[46],"one":[50,153],"cannot":[51],"underscore":[52],"importance":[54],"target":[57],"promise":[60],"game":[63],"changing":[64],"modifier.":[66],"Several":[67],"pharmaceutical":[68],"companies,":[69,71],"biotech":[70],"academic":[73],"institutions":[74],"raged":[75],"quest":[78,165],"unravel":[80],"biology":[82],"discover":[84],"inhibitors,":[89],"some":[90],"which":[92,155,232],"went":[93],"through":[94],"clinical":[95,161,223],"trials.":[96],"However,":[97],"conundrum":[99],"what":[101],"happened":[102],"fate":[105],"AstraZeneca's":[108],"inhibitors":[110],"undertaking":[113],"find":[115],"that":[118],"could":[119,233],"control":[120],"glycogen":[121],"metabolism":[122],"aberrant":[124],"tau":[125,169],"hyperphosphorylation":[126],"brain,":[129],"rescue":[131],"synaptic":[132],"dysfunction":[133],"has":[134],"largely":[135],"untold.":[137],"AstraZeneca":[138],"was":[139],"forefront":[142],"research":[147],"with":[148,245],"six":[149],"candidates,":[152],"progressed":[156],"up":[157],"Phase":[159],"II":[160],"trials":[162],"untangle":[167],"hypothesis":[170],"AD.":[172],"Analysis":[173],"key":[175],"toxicity":[176],"issues,":[177],"serendipitous":[178],"findings":[179],"efficacy,":[181],"biomarker":[183],"considerations":[184],"relation":[186],"safety":[188],"margins":[189],"limited":[191],"potential":[193],"small":[195],"molecule":[196],"therapeutics":[197],"way":[200],"forward.":[201],"To":[202],"guide":[203],"future":[204],"innovation":[205,276],"this":[207],"important":[208],"target,":[209],"we":[210],"reveal":[211],"roller":[213],"coaster":[214],"journey":[215],"comprising":[216],"two":[218],"preclinical":[221],"at":[227],"AstraZeneca;":[228],"understanding":[230],"lead":[234],"improved":[236],"therapies":[238],"disease.":[240],"These":[241],"learnings":[242],"combination":[244],"advances":[246],"achieving":[248],"kinase":[249],"selectivity,":[250],"different":[251],"modes":[252],"action":[254],"well":[256],"recent":[259],"novel":[262],"conjugated":[263],"peptide":[264],"technology":[265],"targeting":[266],"specific":[267],"tissues":[268],"potentially":[270],"provided":[271],"venue":[273],"scientific":[275],"new":[279],"beginning":[280],"discovery.":[284]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2802853266","counts_by_year":[{"year":2026,"cited_by_count":8},{"year":2025,"cited_by_count":18},{"year":2024,"cited_by_count":9},{"year":2023,"cited_by_count":14},{"year":2022,"cited_by_count":18},{"year":2021,"cited_by_count":15},{"year":2020,"cited_by_count":17},{"year":2019,"cited_by_count":4}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2018-05-17T00:00:00"}
